augmentin 500 mg/125 mg apvalkotās tabletes
glaxosmithkline trading services limited, ireland - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 500 mg/125 mg
augmentin fruit 400 mg/57 mg/5 ml pulveris iekšķīgi lietojamas suspensijas pagatavošanai
glaxosmithkline trading services limited, ireland - amoxicillinum, skābes clavulanicum - pulveris iekšķīgi lietojamas suspensijas pagatavošanai - 400 mg/57 mg/5 ml
augmentin 400 mg/57 mg/5 ml pulveris iekšķīgi lietojamas suspensijas pagatavošanai
glaxosmithkline latvia, sia, latvija - amoxicillinum, skābes clavulanicum - pulveris iekšķīgi lietojamas suspensijas pagatavošanai - 400 mg/57 mg/5 ml
augmentin 1000 mg/200 mg pulveris injekciju/infūziju šķīduma pagatavošanai
glaxosmithkline trading services limited, ireland - amoxicillinum, skābes clavulanicum - pulveris injekciju/infūziju šķīduma pagatavošanai - 1000 mg/200 mg
amoxicillin/clavulanic acid aurobindo 500 mg/125 mg apvalkotās tabletes
aurobindo pharma (malta) limited, malta - amoxicillinum, skābes clavulanicum - apvalkotās tabletes - 500 mg/125 mg
amoxicillin/clavulanic acid aurobindo 875 mg/125 mg apvalkotās tabletes
aurobindo pharma (malta) limited, malta - amoxicillinum, skābes clavulanicum - apvalkotās tabletes - 875 mg/125 mg
augmentin 875 mg/125 mg apvalkotās tabletes
glaxosmithkline trading services limited, ireland - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 875 mg/125 mg
efmody
diurnal europe b.v. - hydrocortisone - adrenal hyperplasia, congenital - kortikosteroīdi sistēmiskai lietošanai - treatment of congenital adrenal hyperplasia (cah) in adolescents aged 12 years and over and adults.
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiski līdzekļi - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.